| Emitents | Grindeks, AS (5299006DWR32NKWM1O86) |
| Veids | Citi |
| Valoda | EN |
| Statuss | Publicēts |
| Versija | |
| Datums | 2009-03-20 09:41:48 |
| Versijas komentārs | |
| Teksts |
Responding to publications in media of March 20, 2009 “Grindeks” informs about its development plans of daughter company in Estonia – “Tallinn pharmaceutical plant”. In the background of worldwide financial and economical crises “Grindeks” considers two opportunities of development ointment business in the future - to move daughter company’s “Tallinn pharmaceutical plant” manufacturing processes to Latvia or to continue manufacturing in Estonia. Management of “Grindeks” will make final decision during year 2009. About “Tallinn pharmaceutical plant” “Tallinn pharmaceutical plant” specializes in ointments manufacturing and currently produces six sorts of ointment medications. The “Tallinn pharmaceutical plant” was founded in 1914, it is one of the largest pharmaceutical plants in the state. In 1998 JSC “Grindeks” bought majority of stakes of the plant. To improve the governance of the concern, optimizing the processes of the “Tallinn pharmaceutical plant” and to achieve strategic goals, “Grindeks” bought out all the shares of minority shareholders, becoming its unique owner in 2004. About JSC “Grindeks” JSC “Grindeks” is the leading pharmaceutical company in the Baltic States. Its main fields of action are: research, development and manufacturing of brand products, generics and active pharmaceutical ingredients. “Grindeks” specializes in the heart and cardiovascular, CNS and anti-cancer medication therapeutic groups. A range of “Grindeks’s” products covers a successful combination of original products and generics, with the original products Mildronate® and Ftorafur® and more than 100 forms of effective and safe generics included therein. “Grindeks” concern consists of four subsidiary companies in Latvia, Estonia and Russia, as well representatives and representative offices in fourteen countries. Products of the company are exported to more than 40 countries and its export comprises more than 96% of the total turnover. The main markets are: the Baltic States, Russia and other CIS countries, Japan, USA. “Grindeks” shares are listed in the Official List of “NASDAQ OMX Riga”. Contacts: Laila Kļaviņa Head of the Communications Department JSC “Grindeks” Phones: +371 67083370, + 371 29256012 e-mail: laila.klavina@grindeks.lv |
| Pielikumi |
|